Virdante Pharmaceuticals Garners $47,750,000 New Financing

  • Feed Type
  • Date
    10/29/2009
  • Company Name
    Virdante Pharmaceuticals
  • Mailing Address
    14 Cambridge Center Bldg 1 Cambridge, MA 02142
  • Company Description
    Virdante is a privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders.
  • Website
    http://www.virdante.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $47,750,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Virdante also announced today that the Company plans to use the proceeds from the new financing to pursue development of a second drug, a sialylated recombinant IgG Fc fragment (“sFc”), the segment of IgG responsible for the anti-inflammatory activity of IVIG. In addition, Virdante plans to expand the application of its Sialic Switch technology to improve the potency of important anti-inflammatory antibodies such as anti-TNF drugs.
  • M&A Terms
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    Osage Ventures
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Venrock
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Biogen Idec Inc.

By posting a comment, you agree to our terms and conditions.